An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate

被引：0
|
作者：
T Leguay
V Desplat
V Lagarde
G Marit
J Reiffers
F-X Mahon
机构：
[1] Laboratoire hématopoïèse leucémique et cible thérapeutique INSERM E0217,
[2] Université Victor Segalen Bordeaux II,undefined
[3] Service des Maladies du Sang,undefined
[4] Hôpital du Haut-Lévèque,undefined
来源：
Leukemia | 2005年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1671 / 1673
页数：2
相关论文
共 50 条
  • [21] Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
    Donato, NJ
    Wu, JY
    Stapley, J
    Lin, H
    Arlinghaus, R
    Aggarwal, B
    Shishodin, S
    Albitar, M
    Hayes, K
    Kantarjian, H
    Talpaz, M
    CANCER RESEARCH, 2004, 64 (02) : 672 - 677
  • [22] Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
    MacPartlin, M.
    O'Hare, T.
    Bumm, T.
    Goss, V.
    Lee, K.
    Corbin, A.
    Stoffregen, E. A.
    Smith, C.
    Johnson, K.
    Moseson, E.
    Griswold, I.
    Wood, L.
    Polakiewicz, R.
    Druker, Brian J.
    Deininger, Michael W. N.
    BLOOD, 2006, 108 (11) : 283B - 283B
  • [23] Interplay between Kinase Domain Autophosphorylation and F-Actin Binding Domain in Regulating Imatinib Sensitivity and Nuclear Import of BCR-ABL
    Preyer, Martin
    Vigneri, Paolo
    Wang, Jean Y. J.
    PLOS ONE, 2011, 6 (02):
  • [24] Spectrum of BCR-ABL Kinase Domain Mutations in North Macedonia in Patients With CML Resistant to Imatinib
    Stojanovska-Jakimovska, Simona
    Cvetanoski, Milche
    Ridova, Nevenka
    Trajkova, Sanja
    Popova-Labachevska, Marija
    Mojsovska, Tara
    Dukovski, Dushko
    Pivkova-Veljanovska, Aleksandra
    Stojanovski, Zlate
    Krstevska-Balkanov, Svetlana
    Pavkovic, Marica
    Chadievski, Lazar
    Panovska-Stavridis, Irina
    Ivanovski, Martin
    Gjorgievska, Emilija
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S375 - S375
  • [25] Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to imatinib
    Irving, JAE
    O'Brien, S
    Lennard, AL
    Minto, L
    Lin, F
    Hall, AG
    CLINICAL CHEMISTRY, 2004, 50 (07) : 1233 - 1237
  • [26] Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, ST1571)
    La Rosée, P
    Corbin, AS
    Stoffregen, EP
    Deininger, MW
    Druker, BJ
    CANCER RESEARCH, 2002, 62 (24) : 7149 - 7153
  • [27] The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate
    Schuster, C
    Forster, K
    Dierks, H
    Elsässer, A
    Behre, G
    Simon, N
    Danhauser-Riedl, S
    Hallek, M
    Warmuth, M
    BLOOD, 2003, 101 (02) : 655 - 663
  • [28] Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects
    B Perazzona
    H Lin
    T Sun
    Y Wang
    R Arlinghaus
    Oncogene, 2008, 27 : 2208 - 2214
  • [29] INCREASING BCR-ABL EXPRESSION LEVELS AND/OR OCCURRENCE OF ABL POINT MUTATIONS NOT ALWAYS PREDICT RESISTANCE TO IMATINIB MESYLATE IN BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
    Grammatico, S.
    Elia, L.
    Vitale, A.
    Matarazzo, M.
    Falciani, V
    Rago, A.
    Cenfra, N.
    Peluso, A. L.
    Pedace, L.
    Grammatico, P.
    Pane, F.
    Meloni, G.
    Foa, R.
    Cimino, G.
    HAEMATOLOGICA, 2008, 93 : S88 - S89
  • [30] Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects
    Perazzona, B.
    Lin, H.
    Sun, T.
    Wang, Y.
    Arlinghaus, R.
    ONCOGENE, 2008, 27 (15) : 2208 - 2214
12345